Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Assessment of Valproate on Ethanol Withdrawal
NCT03235531Phase 4Terminated
- Sponsor
- CAMC Health System
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 4, randomised trial of valproic acid in alcohol withdrawal syndrome (AWS) (2 arms), sponsored by CAMC Health System. Primary endpoint: Lorazepam use in patient monitored with CIWA at 3 weeks. Started Jul 2017; status: terminated.
02
Drugs
valproic acid
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT03235531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235531.